Abstracts Archive - Page 991 of 2425 - ACR Meeting Abstracts

Abstract Number: 550 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Rene Westhovens ², Kevin Winthrop ³, Susan Lee ⁴, Joy Greer ⁴, Adam DeZure ⁴, Di An ⁴, Lei Ye ⁴, John Sundy ⁴, Robin Besuyen ⁵, Luc Meuleners ⁵, Rieke Alten ⁶ and Mark Genovese ⁷, ¹University of California, San Diego School of Medicine, La Jolla, CA, ²University Hospitals, Leuven, Belgium, ³Oregon Health and Science University, Portland, OR, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Schlosspark-Klinik University Medicine, Berlin, Germany, ⁷Stanford University, Stanford, CA
Background/Purpose: Filgotinib (FIL) is an oral selective Janus kinase (JAK1) inhibitor. In studies to date, FIL has been shown to be effective and safe in…
Abstract Number: 551 • 2019 ACR/ARP Annual Meeting
Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Martin Bergman¹, Yoshiya Tanaka ², Gustavo Citera ³, Sami Bahlas ⁴, Mira Ali ⁵, Sebastian Meerwein ⁶, Yanna Song ⁷ and Vibeke Strand ⁸, ¹Drexel University College of Medicine, Stockholm, Sweden, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁴Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chiacgo, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁸Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 vs JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 552 • 2019 ACR/ARP Annual Meeting
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Herbert Kellner¹, ¹Praxis Prof. Herbert Kellner, Munich, Germany
Background/Purpose: Background: Biosimilar TNFα inhibitors have only become available in the last few years. Etanercept bisosimilar SB-4 Benepali® has been launched in March 2016 in…
Abstract Number: 553 • 2019 ACR/ARP Annual Meeting
Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study
Marc Schmalzing¹, Ayman Askari ², David Walsh ³, Maria Carmen Castro ⁴, Francisco J. De Toro ⁵, Slawomir Jeka ⁶, Herbert Kellner ⁷, Hilke Friccius-Quecke ⁸, Fabricio Furlan ⁸, Sohaib Hachaichi ⁸ and Tom Sheeran ⁹, ¹Universitätsklinikum Würzburg, Department of Rheumatology/ Clinical Immunology, Wuerzburg, Germany, ²Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, England, United Kingdom, ³Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵University Hospital A Coruña, A Coruña, Spain, ⁶University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁷Praxis Prof. Herbert Kellner, Munich, Germany, ⁸Hexal AG, a Sandoz company, Holzkirchen, Germany, ⁹Cannock and Wolverhampton Hospitals, Staffordshire, United Kingdom
Background/Purpose: GP2015 is an etanercept biosimilar approved for moderate to severely active rheumatoid arthritis (RA), severe active ankylosing spondylitis (AS), and active and progressive psoriatic…
Abstract Number: 554 • 2019 ACR/ARP Annual Meeting
Evidence to Guide Glucocorticoid Tapering Is Lacking in RA
Beth Wallace¹, David Wallace ², Akbar Waljee ³ and Daniel Clauw ⁴, ¹Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Division of General Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Over a third of RA patients are managed with long-term oral glucocorticoids (GC), defined as daily GC use for ≥3 months[1]. Due to dose-dependent…
Abstract Number: 555 • 2019 ACR/ARP Annual Meeting
Oncostatin M Receptor (OSMR) Underexpression in Patients with Ankylosing Spondylitis
Maria Andreza Correia ¹, Claudia Marques¹, Anderson Almeida ¹, Vitor Silva ¹, Nara Cavalcanti ¹, Moacyr Rego ¹, Angela Duarte ¹ and Maira Pitta ², ¹Universidade Federal de Pernambuco, Recife, Brazil, ²Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
Background/Purpose: Oncostatin M receptor (OSMR), that binding to oncostatin M (OSM) cytokine are associated with inflammation and cell's growth and differentiation. OSM uses the OSMR to…
Abstract Number: 556 • 2019 ACR/ARP Annual Meeting
The Correlation of Bone Bridge and Low Bone Mineral Density Measured by Quantitative Computed Tomography in Patients with Ankylosing Spondylitis
So-Yun Lee¹, Sang Wan Chung ¹, Ran Song ², Hyung-In Yang ¹ and Sang-Hoon Lee ¹, ¹School of Medicine, Kyung Hee University, seoul, Republic of Korea, ²School of Medicine, Kyung Hee University, seoul
Background/Purpose: Chronic inflammation of the spine leads not only to new bone formation in axial joints and vertebral spaces, but also to bone resorption leading…
Abstract Number: 557 • 2019 ACR/ARP Annual Meeting
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey
Theresa Hunter¹, David Sandoval ², Nicola Booth ³, Elizabeth Holdsworth ⁴ and Atul Deodhar ⁵, ¹Eli Lilly and Company, Indianapolis, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Manchester, England, United Kingdom, ⁵Oregon Health & Science University, Portland, OR
Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
Abstract Number: 558 • 2019 ACR/ARP Annual Meeting
Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center
Itziar Calvo-Zorrilla¹, María Luz García-Vivar ¹, Oihane Ibarguengoitia-Barrena ¹, David Montero-Seisdedos ¹, Lucía Vega-Alvarez ¹, Juan María Blanco-Madrigal ¹, Olaia Begoña Fernandez-Berrizbeitia ¹, María Esther Ruiz-Lucea ¹, Ignacio Torre-Salaberri ¹, Ana Rosa Intxaurbe-Pellejero ¹, Clara Eugenia Pérez-Velasquez ¹, Eduardo Cuende-Quintana ¹, Natalia Andrea Rivera-García ¹, María Jesus Allande-López-Linares ¹, Helena Ugarte-Zuazo ¹, Iñigo Gorostiza-Hormaeche ² and Eva Galíndez-Agirregoikoa ¹, ¹Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ²Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain
Background/Purpose: Inflammatory bowel disease (IBD) is an extra-articular manifestation that can appear in spondyloarthritis (SpA), as well as uveitis and psoriasis. Its prevalence is 5-10%,…
Abstract Number: 559 • 2019 ACR/ARP Annual Meeting
Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis
Manouk de Hooge¹, Floris van Gaalen ², Marleen van de Sande ³, Roberta Ramonda ⁴, Karen Fagerli ⁵, Lennart Jacobsson ⁶, Désirée van der Heijde ², Dirk Elewaut ¹ and Filip Van den Bosch ¹, ¹Ghent University Hospital, Ghent, Belgium, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University of Padova, Padova, Italy, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of Göteborg, Göteborg, Sweden
Background/Purpose: A recent study in German chronic back pain (CBP) patients (pts) with a suspicion of axial spondyloarthritis (axSpA) report on the performance of, among…
Abstract Number: 560 • 2019 ACR/ARP Annual Meeting
Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort
Daniel WENDLING¹, Clément PRATI ², Alain Saraux ³, Anna Moltó ⁴, Thao PHAM ⁵, Maxime Dougados ⁶ and Xavier GUILLOT ⁷, ¹Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ²University Teaching Hospital (CHRU), Besançon, France, ³CHU de la Cavale-Blanche Brest, Brest, France, ⁴Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁵CHU, Marseille, France, ⁶Cochin Hospital, Paris, France, ⁷CHU, Saint Denis de la Réunion, Reunion
Background/Purpose: Dactylitis is a particular feature shared across the several phenotypical forms of spondyloarthritis (SpA), part of the classification criteria. There are only few data…
Abstract Number: 561 • 2019 ACR/ARP Annual Meeting
Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)
Eerik Ahomaa ¹, Uta Kiltz², Björn Bühring ³, Xenofon Baraliakos ⁴, Salima van weely ⁵ and Jürgen Braun ⁶, ¹Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, ²Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: In patients with axial spondyloarthritis (axSpA) physical functioning is frequently impaired. The current gold standard to assess physical functioning is self-reported questionnaires (i.e. BASFI),…
Abstract Number: 562 • 2019 ACR/ARP Annual Meeting
Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis
Uta Kiltz¹, Robert B.M. Landewé ², Désirée van der Heijde ³, Martin Rudwaleit ⁴, Michael Weisman ⁵, Nurullah Akkoç ⁶, Annelies Boonen ⁷, Jan Brandt-Jürgens ⁸, Philippe Carron ⁹, Maxime Dougados ¹⁰, Laure Gossec ¹¹, Merryn Jongkees ¹², Pedro Machado ¹³, Helena Marzo-Ortega ¹⁴, Anna Molto ¹⁵, Victoria Navarro-Compán ¹⁶, Karin Niedermann-Schneider ¹⁷, Percival Degrava Sampaio-Barros ¹⁸, Gleb Slobodin ¹⁹, Filip Van den Bosch ⁹, Astrid van Tubergen ²⁰, Salima van weely ²¹, Dieter Wiek ²² and Jürgen Braun ²³, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ⁷Maastricht University Medical Center, Maastricht, Netherlands, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Ghent University Hospital, Ghent, Belgium, ¹⁰10Rheumatology B Department, Paris Descartes University, Cochin Hospital, Paris, France, ¹¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ¹²seaynmedical, Netherlands, Netherlands, ¹³Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ¹⁵Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, ¹⁶University Hospital La Paz, IdiPaz, Madrid, Spain, ¹⁷ZHAW Gesundheit Institut für Physiotherapie, Winterthur, Switzerland, ¹⁸Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil, ¹⁹18Department of Internal Medicine A, Bnai Zion Medical Center, Technion, Haifa, Israel, ²⁰Maastricht University Medical Centre and Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands, ²¹Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ²²patient research partner, Germany, Germany, Germany, ²³Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: There is wide variation in the management of patients with axial spondyloarthritis (axSpA) worldwide with significant unmet needs such as delayed diagnosis. One way…
Abstract Number: 563 • 2019 ACR/ARP Annual Meeting
The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study
Rikke Andreasen¹, Lars Erik Kristensen ², Kenneth Egstrup ¹, Xenofon Baraliakos ³, Vibeke Strand ⁴, Hans Christian Horn ⁵, Inger Marie Hansen ¹, Robin Christensen ⁶ and Torkell Ellingsen ⁷, ¹Odense University Hospital, Svendborg, Svendborg, Denmark, ²Musculoskeletal Statistics Unit, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany, Herne, Germany, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Denmark, ⁶Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital & Department of Rheumatology, Institute of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark
Background/Purpose: To explore the impact of sex and disease classification on outcomes in axial spondyloarthritis (axSpA) patients, including both ankylosing spondylitis (AS) and non-radiographic (nr-)…
Abstract Number: 564 • 2019 ACR/ARP Annual Meeting
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis
Jae-Bum Jun¹, Bon San Koo ², Seunghun Lee ³, Jinju Kim ⁴, Juyeon Kang ¹ and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ³Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Novartis Korea Ltd., Seoul
Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].